Natural Ways to Control Thyroid :Releasing T-4-Thyroxine & T-3-Triiodothyronine
Keywords:
Thoiroid,Hormones,T-4-Thyroxin,T-3-Triiodothyronine Etc.Abstract
Excess limit of Thyroid (due to the deficiency of Iodine) is the cause of various diseases like Prikson / Alzhimer etc. Thyroid is a butterfly shaped gland at the base of neck which produces T-3 and T-4 hormones to control the use of the rate of the use of carbohydrate and fats by the cells of body and swelling at the neck too. Iodine deficiency disorders, which include goiter also , are a group of diseases that result from a relative lack of iodine in the diet. It is the single most common cause ofpreventable mental retardation and 38% of the world’s population are said to be at risk fromlackof I2. Medical intervention techniques, for example iodization of table salt, are well-established and have been responsible for reducing the global problem. This report summarizes our study of environmental factors implicated in producing iodine-deficient environments and how an improved understanding of iodine geochemistry can be used to reduce the Iodene Lack problems risks. In the areas proper in iodine in the environment the study is summarized.With a better knowledge of the geochemical behavior ofThyroid and its migration through the food chain we can suggest environmental solutions for reducing. The natural content can be better managed to achieve a more favorable supply of bioavailable Thyroid. The retention of this mobile trace element Iodene in the soil has to be encouraged but it must not become so strongly fixed that it is no longer bioavailable. The soil Eh/pH, organic content, and soil texture are seen to be important controlling factors.
References
Helfand M. Screening for Thyroid Disease. Rockville, MD: Agency for Healthcare Research and Quality; 2004.
October 2014]. Systematic Evidence Review No. 23. Accessed at http://www.ahrq.gov/downloads
/pub/prevent/pdfser/thyrser.pdf. [PubMed]
Hollowell JG, Staehling NW, Flanders WD, Hannon WH, Gunter EW, Spencer CA, et al. Serum TSH, T4, and
thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey
(NHANES III). J Clin Endocrinol Metab. 2002;87(2):489–99. [PubMed]3. Canaris G, Manowitz N, Mayor G, Ridgway E. The Colorado thyroid disease prevalence study. Arch Intern
Med. 2000;160(4):526–34. [PubMed]
Rodondi N, den Elzen WP, Bauer DC, Cappola AR, Razvi S, Walsh JP, et al. Subclinical hypothyroidism and
the risk of coronary heart disease and mortality. JAMA. 2010;304(12):1365–74. [PMC free article] [PubMed]
Ochs N, Auer R, Bauer DC, Nanchen D, Gussekloo J, Cornuz J, et al. Meta-analysis: subclinical thyroid
dysfunction and the risk for coronary heart disease and mortality. Ann Intern Med. 2008;148(11):832–45. [PubMed]
Gencer B, Collet TH, Virgini V, Bauer DC, Gussekloo J, Cappola AR, et al. Subclinical thyroid dysfunction and
the risk of heart failure events: an individual participant data analysis from 6 prospective cohorts. Circulation.
;126(9):1040–9. [PMC free article] [PubMed]
Collet TH, Gussekloo J, Bauer DC, den Elzen WP, Cappola AR, Balmer P, et al. Subclinical hyperthyroidism
and the risk of coronary heart disease and mortality. Arch Intern Med. 2012;172(10):799–809. [PMC free article]
[PubMed]
Surks MI, Ortiz E, Daniels GH, Sawin CT, Col NF, Cobin RH, et al. Subclinical thyroid disease: scientific
review and guidelines for diagnosis and management. JAMA. 2004;291(2):228–38. [PubMed]
Wirth CD, Blum MR, da Costa BR, Baumgartner C, Collet TH, Medici M, et al. Subclinical thyroid dysfunction
and the risk for fractures: a systematic review and meta-analysis. Ann Intern Med. 2014;161(3):189–99. [PMC free
article] [PubMed]
Gharib H, Tuttle R, Baskin H, Fish L, Singer P, McDermott M. Consensus statement: subclinical thyroid
dysfunction: a joint statement on management from the American Association of Clinical Endocrinologists, the
American Thyroid Association, and the Endocrine Society. J Clin Endocrinol Metab. 2005;90(1):581–5. [PubMed]
Diez JJ, Iglesias P. Spontaneous subclinical hypothyroidism in patients older than 55 years: an analysis of
natural course and risk factors for the development of overt thyroid failure. J Clin Endocrinol Metab.
;89(10):4890–7. [PubMed]
Rosario PW. Natural history of subclinical hyperthyroidism in elderly patients with TSH between 0.1 and 0.4
mIU/L: a prospective study. Clin Endocrinol. 2010;72:685–8. [PubMed]
Gussekloo J, van Exel E, de Craen AJ, Meinders AE, Frolich M, Westendorp RG. Thyroid status, disability
and cognitive function, and survival in old age. JAMA. 2004;292(21):2591–9. [PubMed]
U.S. Preventive Services Task Force. Screening for Thyroid Disease: Recommendation Statement. Rockville,
MD: Agency for Healthcare Research and Quality; 2004.15. Helfand M. Screening for subclinical thyroid dysfunction in nonpregnant adults: asummary of the evidence for
the U.S. Preventive Services Task Force. Ann Intern Med. 2004;140(2):128–41. [PubMed]
IMS Institute for Healthcare Informatics. The Use of Medicines in the United States: Review of 2010. 2011. [1
October 2014]. Accessed at http://www.imshealth.com/deployedfiles/imshealth/Global/Content
/IMS%20Institute/Static%20File/IHII_UseOfMed_report.pdf.
Somwaru LL, Arnold AM, Cappola AR. Predictors of thyroid hormone initiation in older adults: results from
the cardiovascular health study. J Gerontol A Biol Sci Med Sci.2011;66(7):809–14. [PMC free article] [PubMed]
Rugge B, Balshem H, Sehgal R, Relevo R, Gorman P, Helfand M. Comparative Effectiveness Review No. 24.
Rockville, MD: Agency for Healthcare Research and Quality; 2011. [1 October 2014]. Screening and Treatment of
Subclinical Hypothyroidism or Hyperthyroidism. AHRQ Publication No. 11(12)-EHC033-EF. Accessed at
http://www.ncbi.nlm.nih.gov/books/NBK83496/ [PubMed]
Jameson J. Disorders of the thyroid gland. In: Fauci A, Braunwald E, Kasper D, Houser S, Longo D, Jameson
J, editors. Harrison's Principles of Internal Medicine. New York: McGraw-Hill; 2008. pp. 2224–46.
Atzmon G, Barzilai N, Hollowell JG, Surks MI, Gabriely I. Extreme longevity is associated with increased
serum thyrotropin. J Clin Endocrinol Metab. 2009;94(4):1251–4. [PMC free article] [PubMed]
Simonsick EM, Newman AB, Ferrucci L, Satterfield S, Harris TB, Rodondi N, et al.Subclinical
hypothyroidism and functional mobility in older adults. Arch Intern Med. 2009;169(21):2011–7. [PMC free article]
[PubMed]
Surks MI, Hollowell JG. Age-specific distribution of serum thyrotropin and antithyroid antibodies in the US
population: implications for the prevalence of subclinical hypothyroidism. J Clin Endocrinol Metab.
;92(12):4575–82. [PubMed]
Vanderpump MP, Tunbridge WM, French JM, Appleton D, Bates D, Clark F, et al. Theincidence of thyroid
disorders in the community: a twenty-year follow-up of the Whickham Survey. Clin Endocrinol (Oxf).
;43(1):55–68. [PubMed]
Alevizaki M, Saltiki K, Voidonikola P, Mantzou E, Papamichael C, Stamatelopoulos K. Free thyroxine is an
independent predictor of subcutaneous fat in euthyroid individuals. Eur J Endocrinol. 2009;161(3):459–65. [PubMed]
Hak AE, Pols HA, Visser TJ, Drexhage HA, Hofman A, Witteman JC. Subclinical hypothyroidism is an
independent risk factor for atherosclerosis and myocardialinfarction in elderly women: the Rotterdam Study. Ann
Intern Med. 2000;132(4):270–8. [PubMed]
Lindeman RD, Schade DS, LaRue A, Romero LJ, Liang HC, Baumgartner RN, et al. Subclinical
hypothyroidism in a biethnic, urban community. J Am Geriatr Soc. 1999;47(6):703–9. [PubMed]
Vanderpump MP, Tunbridge WM, French JM, Appleton D, Bates D, Clark F, et al. The development of
ischemic heart disease in relation to autoimmune thyroid disease in a 20-year follow-up study of an English
community. Thyroid. 1996;6(3):155–60. [PubMed]
Singh S, Duggal J, Molnar J, Maldonado F, Barsano CP, Arora R. Impact of subclinical thyroid disorders on
coronary heart disease, cardiovascular and all-cause mortality: a meta-analysis. Int J Cardiol. 2008;125(1):41–8.
[PubMed]
Haentjens P, Van Meerhaeghe A, Poppe K, Velkeniers B. Subclinical thyroid dysfunction and mortality: an
estimate of relative and absolute excess all-cause mortality based on time-to-event data from cohort studies. Eur J
Endocrinol. 2008;159:329–41. [PubMed]
Ladenson PW, Singer PA, Ain KB, Bagchi N, Bigos ST, Levy EG, et al. American Thyroid Association
guidelines for detection of thyroid dysfunction. Arch Intern Med. 2000;160:1573–5. [PubMed]
Baskin HJ, Cobin RH, Duick DS, Gharib H, Guttler RB, Kaplan MM, et al. American Association of Clinical
Endocrinologists medical guidelines for clinical practice for the evaluation and treatment of hyperthyroidism and
hypothyroidism. Endocr Pract. 2002;8:457–69. [PubMed]
Stone M, Wallace R. Medicare Coverage of Routine Screening for Thyroid Dysfunction. Washington, DC:National Academy Press; 2003. [PubMed]
********
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Dr. Sadhana Chaurasiya, Dr Vipin Singh

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.